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Introduction 
Rheumatoid arthritis (RA) is the most common inflammatory arthritis 
worldwide. Apart from its well known manifestations involving the joints 
(e.g. deformity, swelling, synovial inflammation), there are widespread, 
extra-articular manifestations that also involve the cardiovascular (CV) 
system.1 The consequences of CV involvement are often serious; 
cerebrovascular disease, ischemic heart disease and CV disease (CVD)-
associated death are up to 50% higher in the context of RA leading to a 
reduction of life-expectancy in these patients of 3-10 years compared with 
the general population.1 To date, no satisfactory explanation of this 
phenomenon has been found, or maybe, it has been overlooked? 
This Viewpoint argues that Cytomegalovirus (CMV) is a major contributor to the 
excess of CVD observed in RA. For over two decades CMV has been implicated in 
both RA and CVD; however, no direct, mechanistic explanations for its role in 
either condition have been found. At the same time, in both conditons 
investigators have observed the expansion of CD4+ T-cells that lack a surface 
marker called CD28 (‘CD4+CD28− T-cells’, sometimes referred to as ‘CD28null’ cells). 
Numerous reports have shown not only a direct contribution of this subset to 
vascular pathology but also a positive correlation between the numbers of these 
cells and the severity of disease/complications, both in regards to RA and CVD.2, 3 
Is this simply a coincidence? 
 It is clearly not, since research has also revealed that expansions of this 
‘pro-atherogenic’ CD4+CD28− subset only occur in CMV-seropositive (CMV+) 
individuals; they do not occur as a result of ageing in CMV-seronegative (CMV−) 
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people, suggesting that ageing contributes to them only inasmuch as it is 
associated with a higher prevalence of CMV infection.4-7 Expansions of CD4+CD28− 
T-cells reported in RA and other autoimune diseases frequently exceed 5-10% 
(when not stratified by CMV infection status) and so vastly exceed the percentages 
observed in CMV− individuals where reported (about 1-2% in the literature). A 
small number of studies in RA and granulomatosis with polyangiitis (GPA) were 
actually stratified by CMV serology and found that the CD4+CD28− T-cell subset 
was increased by 10 to 20-fold in the CMV+ population.4, 6, 7 It is becoming 
increasingly obvious that the expansions of CD4+CD28− T-cells observed in RA are 
explained by the CMV+ population of RA patients; they may also explain the 
increased incidence of CV morbidity and mortality. This is, because, to make things 
worse, CMV infection in RA produces larger expansions of these cells than in 
otherwise healthy people, suggesting RA itself might accelerate these expansions.8 
But, have studies investigating CV complications in RA ever considered the CMV 
infection status of participants?  
The answer is no. This Viewpoint combines evidence from seemingly independent 
lines of investigation to demonstrate that CMV is likely to be a major driver of 
cardiovascular mortality in RA.  
 
The beginning: Cytomegalovirus (CMV) infection in brief 
CMV is best known for causing congenital abnormalities but has been implicated 
in (accelerated) immune senescence, diabetes mellitus (DM), and CVD among 
other conditions. Infection usually occurs in early childhood but may occur at any 
age. Latent infection is present in 40% - 90% of the world’s population. Older 
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people are more likely to carry CMV, however, prevalence depends on a number 
of other factors including race and education.9 Lower socioeconomic status in 
particular is associated with a higher prevalence of CMV infection but also a higher 
prevalence of dyslipidaemia, higher cholesterol, and smoking, which are all risk 
factors for CVD. Despite this complex interrelatedness of risk factors, 
epidemiological evidence supports that CMV infection independently contributes 
to CVD and more recent work identifying CMV as the major driver of CVD in HIV-
infected people supports this view.9 But how does CMV actually cause vascular 
pathology? 
 
First line of investigation: CMV, T-cells, and vascular injury 
The connection between CMV and vascular damage was first made when CMV was 
isolated from atherosclerotic lesions (vascular endothelium is in fact a primary 
target tissue of CMV). We now understand that following CMV infection of 
endothelial cells (EC), their class-II MHC expression is reduced, hampering direct 
CMV-antigen presentation to CD4+ T-cells. However, CMV-infected EC can release 
non-infectious exosomes that are replete with CMV proteins and uptake of these 
by antigen-presenting cells allows effective presentation to and activation of CMV-
specific CD4+ T-cells.10 CD4+ T-cells are directly involved in coronary artery injury, 
which may be driven by the presence of CMV antigens in the vasculature.2  
Work in mouse models has confirmed additional roles for T-cells in causing 
vascular injury, for example by driving hypertension. Mice lacking both T-cells and 
B-cells (Rag -/-) show blunted hypertension in response to angiotensin-II infusion 
or (DOCA)-salt (which are popular mouse models of hypertension). Rag -/- mice 
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also exhibit decreased vascular reactive oxygen species (ROS) production with 
reduced nitric oxide (NO, ‘relaxing factor’) consumption. Adoptive transfer of T-
cells (but not B-cells) restores these responses to normal.11 Additional work in 
mice has revealed that persistent murine CMV (MCMV) infection of EC induces 
renin expression, which subsequently increases local angiotensin-II (ATII). This in 
turn leads to an increase of ROS production by ATII receptor-positive infiltrating 
T-cells. This mechanism causes hypertension within weeks, independently of 
atherosclerotic plaque formation but at the same time contributes to (aortic) 
atherosclerosis.12  
 
Second line of investigation: CMV and autoimmune disease 
A connection between CMV and autoimmune/chronic inflammatory disease has 
been discussed since the early 1990s. CMV infection not only exacerbates 
inflammation in RA, higher anti-CMV antibody levels also associate with more 
frequent surgical procedures and more severe joint damage.6 Moreover, CMV-
specific T-cells are present in RA affected joints. Apart from RA, CMV has been 
directly or indirectly implicated in several other autoimmune and chronic 
inflammatory conditions, including for example Granulomatosis with Polyangiitis, 
Systemic Lupus Erythematosus, or systemic sclerosis.  
Conventional CV risk factors including smoking, physical inactivity, hypertension 
and DM contribute to CV mortality in RA but have reduced predictive value 
compared to patients without RA. RA might itself accelerate atherogenesis, e.g. as 
a consequence of chronic inflammation, related to therapy, or, due to other, as yet 
poorly identified factors.  
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Third line of investigation: CD4+CD28− T-cells in CVD and autoimmune 
disease 
As mentioned above, expansions of CD4+CD28− T-cells have been implicated in 
both CVD and RA. Judging by their combination of adhesion molecules, chemokine 
receptors, and cytolytic molecules, they have a highly cytotoxic, ‘effector’ 
phenotype; they are also resistant to the ‘dampening’ effects of regulatory T-cells. 
This dangerous combination translates into an increased potential for causing 
tissue damage including in the vasculature.2, 3 In acute coronary syndrome (ACS) 
and myocardial infarction, increased numbers of these cells are associated with 
increased immediate mortality and recurrence. Some authors found nearly 10-
fold higher levels of CD4+CD28− T-cells in patients with unstable angina (UA) 
compared to those with stable angina. They so identified the percentage of 
CD4+CD8− T-cells as an independent predictor of future acute coronary events, 
implying that these cells are key-players in mediating atherosclerotic plaque 
injury/instability.13 The number of studies investigating CD4+CD28− T-cells in 
autoimmune and chronic inflammatory disease is impressive. They were most 
extensively characterized in RA patients, where their frequencies correlate 
positively with disease severity and the extent of extra-articular involvement. The 
properties of CD4+CD28− cells and their damaging effects on CV and other tissues 
were the subject of extensive recent reviews.2, 3 
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CD4+CD28- T-cells are the ‘missing link’ between CMV infection and 
increased CVD-associated mortality in RA 
The observation that expansions of CD4+CD28− T-cells exclusively occur in CMV 
infected people inevitably joins up the three lines of investigation we have 
explored and provides a straightforward and convincing explanation for how CMV 
infection drives excess cardiovascular damage in RA.  
Several review articles have distracted from CMV infection as the exclusive trigger 
of CD4+CD28− T-cell expansions by stating that such expansions may also be 
induced in the presence of other infections or be related to cellular senescence.2, 3 
It is surprising though, that none of the clinical studies allegedly supporting a role 
of other pathogens in driving CD4+CD28− T expansions investigated the CMV 
infection status of the participants. While some authors have described the 
induction of CD4+CD28− T-cell during in vitro proliferation experiments, to the 
best of our knowledge, no study has ever reported the presence of CD4+CD28− T-
cell expansions in CMV− individuals. 2, 3   
Only a small number of studies on CD4+CD28− T-cells in autoimmune diseases 
divided participants by CMV infection status. For example, Pierer et al. showed 22-
fold higher and Hooper et al. 10-fold higher numbers of these cells in CMV+ 
compared to CMV− RA patients.6, 7 Morgan et al. reported a 24-fold increase of 
CD4+CD28− T cells in CMV+ compared CMV− GPA patients. In the same study, 
CD4+CD28− T-cell numbers were ‘only’ 14-fold higher in CMV+ compared to CMV− 
healthy controls, suggesting that, as with RA, the underlying condition accelerated 
these expansions.4, 8 In all studies, CMV− patients had low numbers of CD4+CD28− 
T-cells (in the order of 1%) and only CMV+ patients showed expansions of these 
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cells. A compelling observation in renal allograft recipients further confirms the 
role of CMV in driving such expansions; increasing numbers of CD4+CD28− T-cells 
were observed in CMV− recipients of renal allografts only when they received a 
CMV+ graft but not if the graft was CMV−.5 If only CMV-infection drives the expansion 
of CD4+CD28− T-cells, then what is the antigen-specificity of these cells?   
 
It remains unclear to what extent CD4+CD28− T-cells are CMV specific  
Since expansions of CD4+CD28− T cells are induced by CMV infection, they are 
likely to be responsive to CMV antigens. Alternatively, CMV infection might trigger 
cross-reactivity to constitutively expressed antigens, or facilitate reactivity to 
antigens whose expression is induced after CMV infection or as a result of tissue 
damage. In agreement with our own (unpublished) data, it was shown that 
CD4+CD28− T-cells proliferate in response to CMV antigens.5 Others have reported, 
however, that in patients with ACS a proportion of these cells recognize human 
heat shock protein 60 (HSP60) but not a CMV lysate.2 Of note, non-responsiveness 
to a CMV lysate does not rule out CMV reactivity (CMV-lysates do not contain all 
relevant T-cell antigens in sufficient amounts to stimulate effective T-cell 
responses). Interestingly, antibody cross-reactivity between HSP60 and the CMV 
UL122 and US28 proteins has been reported as an indirect mechanism by which 
CMV infection might facilitate EC injury.14 Cross-reactivity of antibodies suggests 
cross-reactivity at the level of T-cells, too. It is important to note, however, that 
the question if CMV-infection drives CD4+CD28− T-cell expansions is not 
predicated on whether these cells are CMV-specific.  
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Should we target CMV and/or CD4+CD28− T-cells in CMV+ RA patients? 
Experimental evidence in man suggests that anti-CMV treatment may be able to 
reduce both reactivity and numbers of CMV-specific T-cells. For example, low dose 
acyclovir (ACV) therapy, used to treat herpes simplex virus, decreases the 
response of CD4+ T-cells to pp65 CMV protein, probably by diminishing the CMV-
antigen load, turnover, and uptake by APCs.15 If CMV-specific T-cells were indeed 
instrumental in mediating CMV-driven vascular damage, anti-viral drugs might be 
a way of slowing down this process. Therapies targeting CD4+CD28− T-cells 
directly have not been investigated to date. Since biologic agents for cell-specific 
treatment are designed to target specific molecules expressed on relevant tissues, 
a molecule specifically expressed on CD4+CD28− T-cells would have to be 
identified. Interestingly, however, anti-TNF therapy appears to reduce the risk of 
myocardial infarction and, along with abatercept has been shown to reduce the 
number of CD4+CD28− T-cells.3 Our knowledge of how other drugs used in RA 
affect CV complications or CD4+CD28− T-cells is, however, limited.  
 
What next? 
Studies systematically evaluating these factors are clearly indicated. We believe 
that CMV infection status has not been given sufficient attention in studies 
investigating CVD, in particular in the context of RA. This may be due to a lack of 
awareness of the damaging effects of CMV beyond congenital disease and specific 
end-organ disease in the immunocompromised or immunosuppressed. The 
widespread clinical consequences of CMV infection and the burden on the immune 
system that it represents are still being underestimated. One important goal of this 
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Viewpoint is to encourage researchers to stratify future CV studies by CMV 
infection status. This would be one important step forward. Future research may 
identify promising new targets for drugs, which could be used adjunctively in 
selected RA patients to reduce CMV-associated CV mortality. 
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Single display item: Facts Box 
CMV as a driver of excess CVD in RA: The facts in short 
 CMV infection has been implicated in CVD and RA for >20 years and is associated 
with increased disease severity and higher numbers of complications. 
 CMV infection drives the expansion of CD4+CD28− T-cells, which are highly potent, 
cytotoxic CD4+ T-cells with an increased propensity to infiltrate and destroy vascular 
tissue. Only very small numbers of CD4+CD28− T-cells occur in CMV-uninfected 
people. 
 CVD and RA are associated with often major expansions of these cells. Their numbers 
correlate with both disease severity and the incidence of complications, however, 
most clinical studies investigating the role of CD4+CD28− T-cells were not stratified 
by CMV infection status. 
 Published research suggests that RA and other chronic inflammatory diseases 
accelerate CD4+CD28− T-cell expansions within the CMV-infected patient population. 
 Routinely stratifying studies in CVD by CMV infection status would be a major step 
forward in raising awareness and addressing the indirect, detrimental effects of CMV 
infection on the CV system. 
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